Category Archives: Professional News

SYL040012 is a novel compound arising from Sylentis’s research in ophthalmological disorders. It is indicated for treating ocular hypertension associated with glaucoma. SYL040012 is a chemical entity under the heading of interference RNA (RNAi). Sylentis is one of only five companies in the world with RNAi-based products undergoing clinical trials. Madrid, 7 June 2013: Sylentis, a […]

SYL1001 is a compound arising from Sylentis’s research in ophthalmological disorders It is indicated for treating eye discomfort associated with dry eye syndrome SYL1001 is a form of interference RNA (RNAi) SYL1001 inhibits the capsaicin receptor TrpV1, which is expressed on the surface of the eye.   Madrid, 27 February 2013: Sylentis, a biopharmaceutical subsidiary […]

Madrid, 9 March 2011: Sylentis (MC:ZEL) presented the main results of its Phase I trial on safety and tolerance of its product SYL040012; the compound proved to be safe in the trial conditions. These results were presented in an oral communication entitled “Phase I Trial with SYL040012: New RNAi-based treatment for glaucoma” at the 7thConference on Glaucoma, […]

SYL1001 is a new compound arising from Sylentis’s research in ophthalmological disorders
It is indicated for treating eye discomfort associated with dry eye syndrome
SYL1001 is a form of interference RNA (RNAi)
SYL1001 inhibits the capsaicin receptor TrpV1, which is expressed on the surface of the eye Madrid, 6 June 2011: Sylentis, […]

SYL040012 is a new compound developed in Sylentis’s R&D programme in ophthalmological disorders such as ocular hypertension and glaucoma. SYL040012 is a form of RNA interference (RNAi). It reduces intraocular pressure by inhibiting the expression of ß-adrenergic receptors. Madrid, 22 November 2010: Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia (MC: ZEL) and a pioneer in the […]